Montanari Floriane, Knasmüller Bernhard, Kohlbacher Stefan, Hillisch Christoph, Baierová Christine, Grandits Melanie, Ecker Gerhard F
Pharmacoinformatics Research Group, Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria.
Front Chem. 2020 Jan 10;7:899. doi: 10.3389/fchem.2019.00899. eCollection 2019.
Transporters expressed in the liver play a major role in drug pharmacokinetics and are a key component of the physiological bile flow. Inhibition of these transporters may lead to drug-drug interactions or even drug-induced liver injury. Therefore, predicting the interaction profile of small molecules with transporters expressed in the liver may help medicinal chemists and toxicologists to prioritize compounds in an early phase of the drug development process. Based on a comprehensive analysis of the data available in the public domain, we developed a set of classification models which allow to predict-for a small molecule-the inhibition of and transport by a set of liver transporters considered to be relevant by FDA, EMA, and the Japanese regulatory agency. The models were validated by cross-validation and external test sets and comprise cross validated balanced accuracies in the range of 0.64-0.88. Finally, models were implemented as an easy to use web-service which is freely available at https://livertox.univie.ac.at.
肝脏中表达的转运蛋白在药物药代动力学中起主要作用,并且是生理性胆汁流动的关键组成部分。抑制这些转运蛋白可能导致药物相互作用甚至药物性肝损伤。因此,预测小分子与肝脏中表达的转运蛋白的相互作用情况可能有助于药物化学家及毒理学家在药物研发过程的早期阶段对化合物进行优先级排序。基于对公共领域可用数据的全面分析,我们开发了一组分类模型,这些模型能够针对小分子预测一组被美国食品药品监督管理局(FDA)、欧洲药品管理局(EMA)及日本监管机构视为相关的肝脏转运蛋白的抑制作用及转运情况。这些模型通过交叉验证和外部测试集进行了验证,交叉验证的平衡准确率在0.64 - 0.88范围内。最后,这些模型被实现为一个易于使用的网络服务,可在https://livertox.univie.ac.at免费获取。